NCT03570450

Phase 1Interventional

Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.

View on ClinicalTrials.gov ↗

Timeline

Start date: Jun 2, 2018
Primary completion: Feb 29, 2020
Completion date: Sep 30, 2020
First posted: —
Last posted: —
Enrollment: 15
Arms / groups: 5 / —
Source: AACT · ingestion pipeline

Sponsors

University of GrenobleLead sponsor
University of BarcelonaCollaborator
University of TampereCollaborator
Assistance Publique - Hôpitaux de ParisCollaborator
Institut National de la Santé Et de la Recherche Médicale, FranceCollaborator
Andaluz Health ServiceCollaborator
ESSEC Business SchoolCollaborator
Saint Anne's HospitalCollaborator
University of Franche-ComtéCollaborator
University of BordeauxCollaborator
University of Caen-NormandieCollaborator
University of ToulouseCollaborator
Etablissement Français du SangCollaborator
European CommissionCollaborator
Masaryk UniversityCollaborator
FinovatisCollaborator
Instituto de Estudios de Ciencias de la Salud de Castilla y León (IECSCYL)Collaborator
Histocell S.L.Collaborator
University of LyonCollaborator
Universidad Autonoma de BarcelonaCollaborator
Institut d'Investigació Biomèdica de Girona Dr. Josep TruetaCollaborator
MedfilesCollaborator
NovadiscoveryCollaborator
Government of FinlandCollaborator
Servicio de Salud de Castilla La Mancha (SESCAM)Collaborator
Spanish National Health SystemCollaborator
University of GrenobleCollaborator
University of GrenobleOverall official - principal investigator
University of Eastern FinlandCollaborator
University of GlasgowCollaborator

Drugs studied

allogeneic adipose derived mesenchymal stem cell

Indications studied

Stroke

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.